OPGx BEST1
Alternative Names: IC-200 - IVERIC Bio; OPGx-BEST1Latest Information Update: 29 Sep 2025
At a glance
- Originator University of Florida Research Foundation; University of Pennsylvania
- Developer Opus Genetics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Bestrophin replacements; Gene transference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Vitelliform macular dystrophy
Most Recent Events
- 22 Sep 2025 Phase-I/II clinical trials in Vitelliform macular dystrophy in USA (Subretinal) (NCT07185256)
- 18 Aug 2025 US FDA approves IND application for OPGx BEST1 in BEST1-related in Opus Genetics
- 18 Aug 2025 Opus Genetics plans a phase I/II trial for Vitelliform macular dystrophy in USA in the second half of 2025